Anti-Neoplastic Cytotoxicity of Gemcitabine-(C(4)-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C(3)-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole

AIMS: Delineate the feasibility of simultaneous, dual selective “targeted” chemotherapeutic delivery and determine if this molecular strategy can promote higher levels anti-neoplastic cytotoxicity than if only one covalent immunochemotherapeutic is selectively “targeted” for delivery at a single mem...

Descripción completa

Detalles Bibliográficos
Autores principales: Coyne, CP, Jones, Toni, Bear, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381351/
https://www.ncbi.nlm.nih.gov/pubmed/25844392
http://dx.doi.org/10.17303/jcrto.2014.203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381351/
https://www.ncbi.nlm.nih.gov/pubmed/25844392
http://dx.doi.org/10.17303/jcrto.2014.203

Ejemplares similares